Metabotropic glutamate receptor agonists for schizophrenia
- 1 February 2008
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 192 (2), 86-87
- https://doi.org/10.1192/bjp.bp.107.045088
Abstract
A drug acting at metabotropic glutamate receptors has recently been reported to be an effective antipsychotic, breaking the rule that only dopamine receptor-blocking drugs have this property. The finding complements accumulating evidence that glutamatergic abnormalities are important in the pathophysiology of schizophrenia.Keywords
This publication has 14 references indexed in Scilit:
- Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophreniaJournal of Psychopharmacology, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugsPharmacology & Therapeutics, 2007
- Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)Journal of Pharmacology and Experimental Therapeutics, 2007
- Glutamatergic drugs for schizophrenia: a systematic review and meta-analysisSchizophrenia Research, 2005
- Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMolecular Psychiatry, 2004
- Glutamate as a therapeutic target in psychiatric disordersMolecular Psychiatry, 2004
- Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceMolecular Psychiatry, 2004
- Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disordersBehavioural Pharmacology, 2003
- The Emerging Role of Glutamate in the Pathophysiology and Treatment of SchizophreniaAmerican Journal of Psychiatry, 2001